Last updated: August 2, 2026
Sandoz is one of the world’s largest generic and biosimilar manufacturers, with a strong position in complex generics, hospital medicines and immunology biosimilars. Its 2023 separation from Novartis created an independent company with approximately $9.6 billion in annual sales and a portfolio exceeding 1,500 medicines. The company’s growth strategy centers on biosimilar scale, complex formulations, injectable products and expanded access in the United States and Europe.
Sandoz’s main competitive strengths are manufacturing breadth, regulatory experience, global distribution and an established biosimilar pipeline. Its principal constraints are price erosion in mature generics, dependence on third-party manufacturing in selected categories, patent litigation exposure and intense competition from Teva, Viatris, Amgen, Celltrion, Biocon Biologics and Samsung Bioepis.
What is Sandoz’s market position in generics and biosimilars?
Sandoz is a global leader in off-patent medicines, with its strongest position in Europe and a significant U.S. presence. The company operates as Sandoz Group AG, headquartered in Basel, Switzerland, with Sandoz Inc. acting as a major U.S. operating and commercial entity.
| Metric |
Sandoz position |
| 2023 net sales |
Approximately $9.6 billion |
| Core business |
Generics and biosimilars |
| Global product portfolio |
More than 1,500 medicines |
| Geographic reach |
Approximately 100 countries |
| Primary growth platform |
Biosimilars and complex generics |
| Principal U.S. regulatory pathways |
ANDA, 351(k) biosimilar and interchangeable biosimilar pathways |
| Public ownership status |
Independent company since October 2023 |
| Parent company before separation |
Novartis |
Sandoz reported 2023 net sales of $9.65 billion, with biosimilars representing a major growth contributor and generics remaining the larger revenue base [1]. The company has described biosimilars as a strategic growth engine because they generally have higher barriers to entry, longer development timelines and more limited competition than conventional oral solids.
The company competes across oncology, immunology, ophthalmology, endocrinology, bone health, respiratory medicine, transplantation, anti-infectives and hospital injectables.
How does Sandoz compare with Teva, Viatris and leading biosimilar companies?
Sandoz has a broader biosimilar heritage than most generic manufacturers, but its commercial scale is smaller than the combined generic and branded portfolios of Teva and Viatris.
| Company |
Strategic profile |
Relative strength |
| Sandoz |
Pure-play generics and biosimilars |
Biosimilar development, European reach, complex products |
| Teva |
Large global generics company with branded assets |
Scale, U.S. distribution, respiratory and CNS franchises |
| Viatris |
Global generics company with legacy Mylan portfolio |
Commercial scale, global manufacturing and complex generics |
| Amgen |
Originator with biosimilar division |
Biologics manufacturing and U.S. commercial infrastructure |
| Biocon Biologics |
Biosimilar-focused manufacturer |
Insulin, oncology and immunology biosimilars |
| Celltrion |
Biologic developer and manufacturer |
Antibody biosimilars and vertically integrated production |
| Samsung Bioepis |
Biosimilar developer with strong partners |
Clinical development and large-molecule execution |
| Fresenius Kabi |
Hospital and injectable specialist |
Parenteral products and institutional distribution |
Sandoz’s competitive differentiation is its combination of biosimilar development and generic manufacturing. Companies such as Celltrion and Samsung Bioepis have strong biologics capabilities but less exposure to traditional generics. Teva and Viatris have greater scale in commodity generics but face broader portfolio complexity and more significant price competition.
Sandoz’s standalone structure allows management to allocate capital directly to biosimilar development rather than balancing generic investment against Novartis’s innovative pharmaceutical pipeline.
What products and biosimilars are protected by Sandoz’s commercial and intellectual-property strategy?
Sandoz does not rely on one company-wide patent estate. Its protection comes from product-specific development know-how, manufacturing processes, formulation patents, regulatory exclusivities, trade secrets, reference-product patent challenges and settlement agreements.
Key U.S. biosimilar products and programs include:
| Sandoz product |
Active ingredient |
Reference product |
U.S. regulatory status |
| Zarxio |
Filgrastim-sndz |
Neupogen |
FDA-approved biosimilar; launched in 2015 |
| Ziextenzo |
Pegfilgrastim-bmez |
Neulasta |
FDA-approved biosimilar; launched in 2018 |
| Hyrimoz |
Adalimumab-adaz |
Humira |
FDA-approved biosimilar; U.S. launch in 2023 |
| Erelzi |
Etanercept-szzs |
Enbrel |
FDA-approved biosimilar; commercial timing constrained by patent settlement |
| Tyruko |
Natalizumab-sztn |
Tysabri |
FDA-approved biosimilar in 2023 |
| Jubbonti |
Denosumab-bbdz |
Prolia |
FDA-approved biosimilar in 2024 |
| Wyost |
Denosumab-bbdz |
Xgeva |
FDA-approved biosimilar in 2024 |
Sandoz also has biosimilar activities involving ustekinumab, ranibizumab and other high-value biologics through development and commercial partnerships. Product availability and launch dates depend on reference-product patents, regulatory exclusivity and negotiated settlements.
What formulation patents protect Sandoz products?
For conventional generics, formulation protection can cover:
- Extended-release matrices
- Injectable stabilizers
- Particle-size distributions
- Device components
- Drug-device combinations
- Solid dispersions
- Sterile manufacturing processes
- Crystalline or polymorphic forms
- Dosage regimens and administration methods
For biosimilars, the most important proprietary assets are often process-related rather than composition-of-matter patents. These include cell-line development, upstream culture conditions, purification sequences, glycosylation control, formulation stability, container closure systems and analytical comparability methods.
Manufacturing know-how can create practical barriers even where a competing company can legally enter. A biosimilar applicant must demonstrate analytical, pharmacokinetic, clinical and manufacturing comparability. Process changes may affect yield, aggregation, immunogenicity and regulatory approval timing.
When does Sandoz lose exclusivity for major biosimilar products?
Sandoz’s products do not have a uniform exclusivity calendar. The relevant date depends on whether the product is a small-molecule generic or a biologic.
Small-molecule generics
A first applicant that successfully challenges listed patents may receive 180 days of generic exclusivity under the Hatch-Waxman framework. The commercial value depends on whether the applicant is first to file, whether other first applicants are eligible and whether the FDA can approve the product after patent litigation.
Small-molecule generic patents are listed in the FDA Orange Book. They may cover the active ingredient, formulation, method of use or drug delivery system [2].
Biosimilars
Biologic reference products receive 12 years of U.S. reference-product exclusivity under the Biologics Price Competition and Innovation Act. Biosimilar products are recorded in the FDA Purple Book rather than the Orange Book [3].
The principal commercial dates depend on:
- Reference-product approval.
- End of the 12-year reference-product exclusivity period.
- Patent litigation under the BPCIA.
- Notice of commercial marketing.
- Any settlement or license agreement.
- Interchangeability status.
- State substitution rules.
A biosimilar may receive approval before commercial launch if litigation or a settlement delays market entry.
What is the Orange Book and Purple Book status of Sandoz products?
Sandoz has products in both regulatory systems.
| Product category |
FDA listing system |
Relevant legal framework |
| Small-molecule generics |
Orange Book |
Hatch-Waxman Act |
| Biosimilars and interchangeable biosimilars |
Purple Book |
BPCIA |
| Generic injectable drugs |
Orange Book, where applicable |
ANDA and patent certification framework |
| Biologic reference products |
Purple Book |
Biologics exclusivity and BPCIA |
Sandoz generic applicants may submit Paragraph IV certifications asserting that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. Reference-product sponsors can respond with patent litigation, potentially triggering a 30-month stay of FDA approval under Hatch-Waxman.
For biosimilars, the BPCIA patent-exchange process, commonly called the patent dance, determines which patents may be litigated before or after commercial launch. The absence of a complete public patent list in the Purple Book means that commercial risk analysis requires review of court filings, licensing agreements and reference-product patent assertions.
Which companies are challenging Sandoz’s products?
Sandoz generally acts as the challenger or biosimilar entrant rather than the patent holder defending an innovative reference product. The company’s relevant counterparties include:
- AbbVie, concerning adalimumab and Humira-related patents.
- Amgen, concerning etanercept, pegfilgrastim and denosumab products.
- Biogen and other parties associated with natalizumab reference-product rights.
- Genentech and Roche, concerning selected oncology and ophthalmology biologics.
- Janssen and Johnson & Johnson, concerning ustekinumab and other immunology products.
Sandoz’s legal exposure comes from both sides of the market. It may challenge reference-product patents to accelerate entry, while competitors may challenge Sandoz’s generic patents, manufacturing patents or regulatory exclusivity positions.
What patent litigation affects Sandoz’s generic and biosimilar portfolio?
Sandoz’s most commercially important litigation relates to high-revenue biologics. The disputes typically involve:
- Invalidity and non-infringement claims.
- Patent term and pediatric-extension calculations.
- Formulation and dosing patents.
- Manufacturing-process patents.
- Drug-device patents.
- Interchangeability and substitution consequences.
- Launch-at-risk decisions.
- Settlement agreements with delayed entry dates.
Humira and Hyrimoz
Humira’s U.S. composition patent expired years before biosimilar entry, but AbbVie asserted later formulation, dosing and manufacturing patents. Sandoz launched Hyrimoz in the United States in 2023 after the broader Humira biosimilar settlement cycle began. The commercial effect was a crowded market with multiple adalimumab biosimilars, payer exclusions and rapid price competition.
Enbrel and Erelzi
Erelzi received FDA approval as a biosimilar to Enbrel. Amgen’s patent estate around etanercept created a longer market-entry barrier than the reference product’s initial regulatory exclusivity period. Sandoz’s U.S. commercial timing has been constrained by patent settlement terms, making Erelzi an example of regulatory approval that does not equal immediate commercial availability.
Prolia and Xgeva
Sandoz received FDA approval for Jubbonti and Wyost in 2024. Denosumab is commercially important because Prolia and Xgeva have substantial U.S. revenue and are used in chronic and oncology settings. Launch timing depends on patent settlements, litigation outcomes, product labeling and payer adoption.
How strong is Sandoz’s patent and manufacturing estate?
Sandoz’s patent estate is strongest where it combines regulatory exclusivity, manufacturing complexity and clinical development data. Its position is weaker in commoditized oral solids with multiple approved suppliers.
| Asset type |
Strategic value |
Sandoz position |
| Active-ingredient patents |
High for innovative products, limited for generics |
Usually challenger rather than owner |
| Formulation patents |
Moderate to high |
Important in injectables and complex dosage forms |
| Process patents |
High for biologics |
Core biosimilar protection and barrier |
| Trade secrets |
High |
Critical to cell culture, purification and yield |
| Device patents |
Moderate |
Relevant to prefilled syringes and delivery systems |
| Regulatory exclusivity |
Temporary but valuable |
Important for biosimilar launch planning |
| Manufacturing capacity |
High |
Major advantage in sterile and biologic products |
| Distribution contracts |
Moderate |
Supports rapid post-approval commercialization |
The company’s manufacturing footprint includes biologic and sterile-product capabilities, but Sandoz also uses contract manufacturing and development partners. Its overall barrier to entry is therefore product-specific rather than uniform across the portfolio.
What generic entry risks exist for Sandoz and its competitors?
The main risks are price compression, supply interruptions and delayed approval caused by patent disputes.
Generic launch scenarios
| Scenario |
Likely market effect |
| One first-to-file generic |
Temporary pricing power and rapid share capture |
| Multiple generic entrants |
Steep price erosion, often within months |
| Biosimilar with interchangeability |
Greater pharmacy substitution potential |
| Biosimilar without interchangeability |
More reliance on physician and payer adoption |
| Launch after patent settlement |
Predictable entry but reduced upside |
| Launch at risk |
Early revenue opportunity with substantial damages exposure |
| Manufacturing delay |
Lost launch window and weakened payer position |
For biosimilars, the principal risk is less about immediate generic substitution and more about contracting. A biosimilar with strong payer access can gain share even without interchangeable designation. Conversely, an interchangeable product may still underperform if the originator controls preferred formulary placement through rebates.
What is Sandoz’s FDA regulatory status?
Sandoz has experience with both ANDA approvals and 351(k) biosimilar approvals. Zarxio was the first biosimilar approved by the FDA under the BPCIA pathway in 2015 [4]. That approval gave Sandoz a long operating history in U.S. biosimilar regulatory submissions.
The company’s U.S. regulatory capabilities include:
- Analytical similarity packages.
- Pharmacokinetic and pharmacodynamic studies.
- Immunogenicity assessment.
- Manufacturing comparability.
- Interchangeability submissions.
- Global reference-product bridging.
- Post-market pharmacovigilance.
- Supplemental indications and labeling strategy.
FDA approval does not guarantee immediate launch. Patent settlements and commercial agreements often determine the effective market-entry date.
What licensing deals support Sandoz’s competitive strategy?
Sandoz uses partnerships to supplement internal development. Important partnership structures include:
- In-licensing of biosimilar candidates.
- Co-development with biotechnology companies.
- Regional commercialization rights.
- Manufacturing and supply agreements.
- Reference-product access agreements.
- Device and delivery-system licenses.
Sandoz has worked with companies including Polpharma Biologics and other development partners on selected biosimilar programs. These agreements reduce internal development burden but can limit margin through royalties, milestone payments and profit-sharing arrangements.
The commercial value of a licensing deal depends on territorial rights, manufacturing control, exclusivity periods, supply obligations, clinical development responsibilities and the treatment of patent litigation costs.
What is Sandoz’s revenue exposure to biosimilars and generics?
Generics remain the larger component of Sandoz’s revenue base, but biosimilars have a higher strategic value because they can produce stronger margins and face fewer qualified competitors.
| Revenue driver |
Exposure |
| Commodity oral generics |
High volume, low margin, intense price competition |
| Complex generics |
Moderate volume, stronger entry barriers |
| Sterile injectables |
Attractive demand, manufacturing and shortage risk |
| Oncology biosimilars |
Large addressable markets, contracting pressure |
| Immunology biosimilars |
High revenue potential, payer-driven price erosion |
| Bone-health biosimilars |
Strong product value, patent and launch-timing risk |
| Hospital products |
Stable institutional demand, tender pricing |
Sandoz’s revenue is exposed to the timing of major biologic entries. A delayed denosumab or immunology launch can affect growth expectations more than a single small-molecule generic approval. The reverse is true for mature generics, where loss of a product or manufacturing disruption may have limited company-wide effect but materially affect a specific product line.
What geographic markets are most important to Sandoz?
Europe is Sandoz’s strongest geographic base, supported by established country organizations, tender participation and broad reimbursement access. The United States is strategically important because biologic reference products generate high revenue and U.S. payers can accelerate biosimilar adoption.
Key markets include:
- United States
- Germany
- France
- Italy
- Spain
- United Kingdom
- Canada
- Japan
- Australia
- Emerging markets in Latin America and Asia
Geographic protection is fragmented. A patent settlement in the United States may not determine entry in Europe, where patent validity, supplementary protection certificates and national litigation can produce different outcomes. Sandoz must manage separate regulatory approvals, local substitution rules, tender systems and reimbursement policies.
How does Sandoz compare with Amgen in biosimilars?
Sandoz has longer experience as a biosimilar entrant, while Amgen has greater originator-biologic manufacturing depth and a strong U.S. commercial platform.
| Factor |
Sandoz |
Amgen |
| Core identity |
Generic and biosimilar company |
Innovative biologics company with biosimilar division |
| Biosimilar experience |
Early and extensive |
Broad, with strong biologic infrastructure |
| Generic portfolio |
Large |
Limited |
| U.S. payer leverage |
Meaningful but smaller |
Strong originator and institutional relationships |
| Manufacturing |
Broad global network |
Large-scale biologic manufacturing |
| Patent role |
Frequent challenger |
Frequent reference-product patent holder |
| Strategic priority |
Biosimilar and generic access |
Defend originator revenue while commercializing biosimilars |
Sandoz is structurally better positioned to pursue multiple off-patent products. Amgen has greater ability to use its biologics manufacturing and clinical infrastructure across both originator and biosimilar products.
What strategic insights matter for investors and business-development teams?
Sandoz’s most defensible opportunities are products with technical barriers and limited competition. These include complex injectables, biosimilars requiring sophisticated analytical packages, ophthalmic products, long-acting formulations and hospital medicines with difficult sterile manufacturing requirements.
The main strategic indicators are:
- FDA approvals for high-revenue biosimilars.
- Interchangeability designations.
- Patent settlements that establish U.S. launch dates.
- Internal manufacturing capacity for biologics and injectables.
- Biosimilar payer contracts.
- Product gross-margin stability after launch.
- Dependence on contract manufacturers.
- Regulatory approval timing in Europe and the United States.
- Litigation outcomes involving formulation and process patents.
- Competitive density at launch.
Sandoz’s separation from Novartis improves strategic focus but removes the balance-sheet and operational support of its former parent. The standalone company must fund biologic development, manufacturing expansion, litigation and commercial infrastructure while managing generic price erosion.
Key Takeaways
- Sandoz is a major global generics and biosimilars company with approximately $9.6 billion in 2023 sales.
- Its strongest competitive assets are biosimilar expertise, complex-product development, global distribution and manufacturing scale.
- Europe is its core market; the United States is the most important market for high-value biosimilar launches.
- Sandoz has FDA-approved biosimilars including Zarxio, Ziextenzo, Hyrimoz, Erelzi, Tyruko, Jubbonti and Wyost.
- Its commercial launch timing is often determined by patent settlements rather than FDA approval alone.
- Orange Book litigation applies mainly to small-molecule generics; biosimilars are governed through the Purple Book and BPCIA framework.
- The company faces severe price erosion in commodity generics and contracting pressure in biosimilars.
- Its strongest future opportunities are complex generics, sterile products, interchangeable biosimilars and biologics with high manufacturing barriers.
FAQs About Sandoz Inc. Competitive Position
Is Sandoz owned by Novartis?
No. Sandoz became an independent publicly traded company through its separation from Novartis in October 2023. Novartis distributed Sandoz shares to its shareholders as part of the spin-off [5].
Does Sandoz manufacture biosimilars in the United States?
Sandoz uses a global manufacturing network that includes internal facilities and external partners. Product-specific manufacturing locations vary by molecule, dosage form and supply agreement.
Which Sandoz biosimilar was the first FDA-approved biosimilar?
Zarxio, filgrastim-sndz, was the first biosimilar approved by the FDA under the U.S. biosimilar pathway in 2015 [4].
Does FDA approval mean a Sandoz biosimilar can launch immediately?
No. Patent litigation, settlement agreements, regulatory exclusivity and commercial contracts can delay launch after FDA approval.
Is Sandoz a stronger biosimilar competitor than Viatris?
Sandoz has a deeper biosimilar heritage, while Viatris has significant global generic scale and commercial reach. The stronger competitor depends on the product, geography, manufacturing capability and payer contracting position.
References
-
Sandoz Group AG. (2024). Annual report 2023. Sandoz Group AG.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2015, March 6). FDA approves first biosimilar product Zarxio. U.S. Department of Health and Human Services.
-
Novartis AG. (2023, October 4). Novartis completes spin-off of Sandoz. Novartis AG.
